quantum dot-based immunohistofluorescence (Quantum Dot Inc)
90
Structured Review
Quantum Dot Inc
quantum dot-based immunohistofluorescence
Quantum Dot Based Immunohistofluorescence, supplied by Quantum Dot Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantum+dot-based+immunohistofluorescence/quantum+dot+based+immunohistofluorescence/pmc04470473-400-2-0
Average 90 stars, based on 1 article reviews
Quantum Dot Based Immunohistofluorescence, supplied by Quantum Dot Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantum+dot-based+immunohistofluorescence/quantum+dot+based+immunohistofluorescence/pmc04470473-400-2-0
Average 90 stars, based on 1 article reviews
quantum dot-based immunohistofluorescence - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy"
Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Journal: Cancer cell
doi: 10.1016/j.ccell.2015.04.010
Figure Legend Snippet: H460 lung cancer xenografts were treated with increasing doses of BDA-366 for 14 days (n = 6 mice per group, 3 sections per animal). Bcl2 and Bax conformation changes were analyzed in tumor tissues at the end of experiments by QD-IHF using anti-Bcl2/BH3 domain antibody or anti-6A7 Bax antibody, respectively, and quantified as described in “Supplemental Experimental Procedures”. Scale bar represents 10 um. Error bars represent ± S.D. See also Figure S5.
Techniques Used:
Related Articles
Immunohistofluorescence:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Immunostaining:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Formalin-fixed Paraffin-Embedded:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Immunohistochemistry:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: In Situ:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Staining:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Amplification:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Fluorescence In Situ Hybridization:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Imaging:Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: BDA-366 induces Bcl2 conformational change in Article Title: Small Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Article Snippet: Quantum dot-based immunohistofluorescence (QD-IHF) technology has recently been developed as a valuable tool for simultaneous and concurrent immunostaining of multiple biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, thereby allowing for quantification of several biomarkers simultaneously on the same tissue slide ( Li et al., 2013 ). Article Title: Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Article Snippet: Cancer is one of the most serious health threats worldwide, with an estimated 12.7 million new cases and 7.6 million cancer deaths in 2008 according to the GLOBOCAN estimates [1].. Although increasingly more cancer patients could be diagnosed and treated early due to the progress in cancer screening and control programs [1,2], the survival of most patients remains poor with no significant reduction in mortality over the past several decades [3–6], especially in develop ing countries [4,7].. It has long been recognized that cancer is not merely a local problem, but a complex systemic disease. Article Title: Small Molecule Bax Agonists for Cancer Therapy Article Snippet: Quantum Dot-based immunohistofluorescence (QD-IHF) and quantification. Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: Article Title: Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer Article Snippet: |